Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India
· Delayed Price · Currency is INR 208.83
+3.28 (1.60%)
Apr 29, 2026, 3:29 PM IST
Jagsonpal Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2021 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2021 - 2017 |
| Cash & Equivalents | 1,061 | 112.15 | 127.6 | 110.53 | 225.26 | Upgrade
|
| Short-Term Investments | - | 1,175 | 1,352 | 1,036 | 245.31 | Upgrade
|
| Cash & Short-Term Investments | 1,061 | 1,287 | 1,479 | 1,146 | 470.57 | Upgrade
|
| Cash Growth | -17.57% | -12.98% | 29.06% | 143.59% | -24.34% | Upgrade
|
| Accounts Receivable | 171.91 | 131.76 | 109.51 | 208.72 | 155.77 | Upgrade
|
| Receivables | 171.91 | 131.76 | 109.51 | 208.72 | 155.77 | Upgrade
|
| Inventory | 146.43 | 152 | 149.97 | 206.76 | 297.42 | Upgrade
|
| Prepaid Expenses | - | 16.62 | 16.02 | 10.68 | 10.62 | Upgrade
|
| Other Current Assets | 51.35 | 24.24 | 212.95 | 73.17 | 156.43 | Upgrade
|
| Total Current Assets | 1,431 | 1,612 | 1,968 | 1,646 | 1,091 | Upgrade
|
| Property, Plant & Equipment | 73.5 | 88.37 | 93.02 | 242.78 | 225.73 | Upgrade
|
| Long-Term Investments | - | 168.62 | 47 | 33.84 | 290.55 | Upgrade
|
| Goodwill | 96.93 | 96.93 | - | - | 0.3 | Upgrade
|
| Other Intangible Assets | 682.67 | 759.24 | - | - | - | Upgrade
|
| Other Long-Term Assets | 882.78 | 57.5 | 62.97 | 27.25 | 34.86 | Upgrade
|
| Total Assets | 3,167 | 2,783 | 2,171 | 1,949 | 1,642 | Upgrade
|
| Accounts Payable | 115.81 | 97.34 | 75.96 | 165.8 | 185.5 | Upgrade
|
| Accrued Expenses | - | 101.99 | 74.19 | 88.86 | 79.86 | Upgrade
|
| Current Portion of Leases | 15.76 | 16.07 | 13.84 | 7.54 | - | Upgrade
|
| Current Income Taxes Payable | 5.57 | - | - | 0.19 | 2.33 | Upgrade
|
| Current Unearned Revenue | - | 9.1 | 12.94 | 6.12 | - | Upgrade
|
| Other Current Liabilities | 145.84 | 34.54 | 14.35 | 7.2 | 2.03 | Upgrade
|
| Total Current Liabilities | 282.98 | 259.04 | 191.28 | 275.71 | 269.72 | Upgrade
|
| Long-Term Leases | 65.89 | 76.32 | 75.57 | 52.47 | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | 44.41 | 30.7 | 20.73 | 21.63 | 32.38 | Upgrade
|
| Other Long-Term Liabilities | 11.77 | 17.04 | 9.18 | 10.75 | 12.56 | Upgrade
|
| Total Liabilities | 405.05 | 383.1 | 296.76 | 360.56 | 314.66 | Upgrade
|
| Common Stock | 133.93 | 132.8 | 132.19 | 130.99 | 130.99 | Upgrade
|
| Additional Paid-In Capital | - | 140.56 | 111.2 | 6 | 6 | Upgrade
|
| Retained Earnings | - | 1,906 | 1,460 | 1,363 | 1,112 | Upgrade
|
| Comprehensive Income & Other | 2,628 | 219.65 | 170.7 | 88.52 | 78.87 | Upgrade
|
| Shareholders' Equity | 2,762 | 2,400 | 1,874 | 1,589 | 1,328 | Upgrade
|
| Total Liabilities & Equity | 3,167 | 2,783 | 2,171 | 1,949 | 1,642 | Upgrade
|
| Total Debt | 81.65 | 92.39 | 89.41 | 60.01 | - | Upgrade
|
| Net Cash (Debt) | 979.55 | 1,195 | 1,390 | 1,086 | 470.57 | Upgrade
|
| Net Cash Growth | -18.02% | -14.03% | 27.96% | 130.84% | -15.07% | Upgrade
|
| Net Cash Per Share | 14.35 | 17.75 | 20.96 | 16.59 | 7.18 | Upgrade
|
| Filing Date Shares Outstanding | 69.34 | 66.4 | 66.09 | 65.5 | 65.5 | Upgrade
|
| Total Common Shares Outstanding | 69.34 | 66.4 | 66.09 | 65.5 | 65.5 | Upgrade
|
| Working Capital | 1,148 | 1,353 | 1,777 | 1,370 | 821.09 | Upgrade
|
| Book Value Per Share | 39.83 | 36.14 | 28.35 | 24.26 | 20.27 | Upgrade
|
| Tangible Book Value | 1,982 | 1,543 | 1,874 | 1,589 | 1,327 | Upgrade
|
| Tangible Book Value Per Share | 28.59 | 23.24 | 28.35 | 24.26 | 20.27 | Upgrade
|
| Land | - | - | - | 87.59 | 87.59 | Upgrade
|
| Buildings | - | - | - | 163.8 | 163.8 | Upgrade
|
| Machinery | - | 14.77 | 20.38 | 18.02 | 329.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.